This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

D. M. Gettelfinger, MD
Dept of Neurology USAF Regional Hospital Sheppard AFB, TX 76311

E. Kokmen, MD
Dept of Neurology Univ of Michigan Ann Arbor, MI 48108

Arch Neurol. 1977;34(12):789.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.—

The patients reported by Drs Castaigne, Laplane, and Bousser are interesting and serve to underscore the dilemma in therapy of cerebrovascular disease, that being the unavailability of satisfactory controlled studies assessing the efficacies of various therapeutic modalities.¹ When such studies are unavailable for arterial occlusive disease, which is much more common, it is not surprising that none exists for venous disease, nor do we expect that one will be forthcoming.

In our series, we specifically excluded those patients with intracranial neoplasm or infection, thus the patients of Dr Castaigne and associates are not strictly comparable. However, this does not resolve the problem that some patients do well and others poorly with apparently similar treatment.

Heparin is commonly believed to discourage the development and propagation of thrombus, but has no known thrombolytic activity. Thus, while heparin might be expected to arrest progression of neurologic symptoms, it is not obvious how . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?